Royal Bank of Canada
CBIO

Royal Bank of Canada’s Crescent Biopharma CBIO Stock Holding History

Royal Bank of Canada’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
51
+31
+155% +$356 ﹤0.01% 6869
2025
Q4 		$0 Hold
20
– – ﹤0.01% 7326
2025
Q3 		$0 Hold
20
– – ﹤0.01% 7268
2025
Q2 		$0 Hold
20
– – ﹤0.01% 7134
2025
Q1 		$0 Hold
20
– – ﹤0.01% 6969
2024
Q4 		$0 Hold
20
– – ﹤0.01% 7017
2024
Q3 		$0 Sell
20
-3
-13% -$63 ﹤0.01% 7068
2024
Q2 		$1K Buy
23
+3
+15% +$312 ﹤0.01% 6819
2024
Q1 		$6K Buy
+20
New +$5.97K ﹤0.01% 6377
2023
Q3 		– Sell
-2
Closed – – 7263
2023
Q2 		$0 Buy
+2
New +$335 ﹤0.01% 7397
2023
Q1 		– Sell
-20
Closed -$6K – 7210
2022
Q4 		$6K Buy
20
+18
+900% +$2.65K ﹤0.01% 6687
2022
Q3 		$0 Buy
+2
New +$144 ﹤0.01% 7595
2021
Q3 		– Sell
-30
Closed -$7K – 7715
2021
Q2 		$7K Sell
30
-5
-14% -$1.27K ﹤0.01% 6972
2021
Q1 		$11K Buy
35
+7
+25% +$2.51K ﹤0.01% 6763
2020
Q4 		$10K Buy
+28
New +$9.81K ﹤0.01% 6369
2020
Q3 		– Hold
0
– – – 6735
2020
Q2 		– Sell
-1
Closed – – 6726
2020
Q1 		$0 Sell
1
-1
-50% -$382 ﹤0.01% 6792
2019
Q4 		$1K Buy
+2
New +$1.08K ﹤0.01% 6649
2018
Q4 		– Sell
-9
Closed -$13K – 6887
2018
Q3 		$13K Buy
+9
New +$13.6K ﹤0.01% 5876
2017
Q4 		– Hold
0
– – – 6660
2017
Q3 		– Hold
0
– – – 6794
2017
Q2 		– Sell
-5
Closed -$3K – 6631
2017
Q1 		$3K Sell
5
-2
-29% -$1.23K ﹤0.01% 6348
2016
Q4 		$4K Buy
+7
New +$4.37K ﹤0.01% 6350
2015
Q1 		– Sell
-1
Closed -$1K – 6239
2014
Q4 		$1K Hold
1
– – ﹤0.01% 6034
2014
Q3 		$1K Hold
1
– – ﹤0.01% 5862
2014
Q2 		$1K Buy
+1
New +$995 ﹤0.01% 5809

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's CBIO Position: Q1 2026 in Review

Royal Bank of Canada increased its Crescent Biopharma (CBIO) stake by 155% in Q1 2026, buying an estimated $356 and bringing the position to 51 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6869.

Royal Bank of Canada first reported a position in CBIO in Q2 2014 and has held it in 23 quarters since. The position peaked at $13K in Q3 2018. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Royal Bank of Canada held 51 shares of Crescent Biopharma worth $1K as of Q1 2026.
  • Royal Bank of Canada bought 31 Crescent Biopharma shares in Q1 2026, an estimated $356.
  • Crescent Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6869 holding.
  • Royal Bank of Canada first reported a position in Crescent Biopharma in Q2 2014 and has held it in 23 quarters since.
  • Royal Bank of Canada's Crescent Biopharma position peaked at $13K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.